Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 2
2004 5
2005 1
2006 5
2007 9
2008 9
2009 7
2010 6
2011 9
2012 12
2013 7
2014 3
2015 5
2016 7
2017 2
2018 1
2019 4
2020 3
2021 8
2022 4
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

106 results

Results by year

Filters applied: . Clear all
Page 1
National Network of Depression Centers position statement: Insurance coverage for intravenous ketamine in treatment-resistant major depressive disorder.
Niciu MJ, Meisner RC, Carr BR, Farooqui AA, Feifel D, Kaplin A, Kendrick EJ, Kim PM, Schneck CD, Vande Voort JL, Parikh SV. Niciu MJ, et al. Among authors: feifel d. J Affect Disord. 2024 Feb 1;346:221-222. doi: 10.1016/j.jad.2023.11.008. Epub 2023 Nov 6. J Affect Disord. 2024. PMID: 37940059 No abstract available.
Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.
Goodwin GM, Croal M, Feifel D, Kelly JR, Marwood L, Mistry S, O'Keane V, Peck SK, Simmons H, Sisa C, Stansfield SC, Tsai J, Williams S, Malievskaia E. Goodwin GM, et al. Among authors: feifel d. Neuropsychopharmacology. 2023 Sep;48(10):1492-1499. doi: 10.1038/s41386-023-01648-7. Epub 2023 Jul 13. Neuropsychopharmacology. 2023. PMID: 37443386 Free PMC article. Clinical Trial.
Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life.
Goodwin GM, Aaronson ST, Alvarez O, Atli M, Bennett JC, Croal M, DeBattista C, Dunlop BW, Feifel D, Hellerstein DJ, Husain MI, Kelly JR, Lennard-Jones MR, Licht RW, Marwood L, Mistry S, Páleníček T, Redjep O, Repantis D, Schoevers RA, Septimus B, Simmons HJ, Soares JC, Somers M, Stansfield SC, Stuart JR, Tadley HH, Thiara NK, Tsai J, Wahba M, Williams S, Winzer RI, Young AH, Young MB, Zisook S, Malievskaia E. Goodwin GM, et al. Among authors: feifel d. J Affect Disord. 2023 Apr 14;327:120-127. doi: 10.1016/j.jad.2023.01.108. Epub 2023 Feb 4. J Affect Disord. 2023. PMID: 36740140 Free article. Clinical Trial.
Pursuing personalized medicine for depression by targeting the lateral or medial prefrontal cortex with Deep TMS.
Zangen A, Zibman S, Tendler A, Barnea-Ygael N, Alyagon U, Blumberger DM, Grammer G, Shalev H, Gulevski T, Vapnik T, Bystritsky A, Filipčić I, Feifel D, Stein A, Deutsch F, Roth Y, George MS. Zangen A, et al. Among authors: feifel d. JCI Insight. 2023 Feb 22;8(4):e165271. doi: 10.1172/jci.insight.165271. JCI Insight. 2023. PMID: 36692954 Free PMC article. Clinical Trial.
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, Burke L, Campbell-Coker K, Carhart-Harris R, Cattell J, Daniel A, DeBattista C, Dunlop BW, Eisen K, Feifel D, Forbes M, Haumann HM, Hellerstein DJ, Hoppe AI, Husain MI, Jelen LA, Kamphuis J, Kawasaki J, Kelly JR, Key RE, Kishon R, Knatz Peck S, Knight G, Koolen MHB, Lean M, Licht RW, Maples-Keller JL, Mars J, Marwood L, McElhiney MC, Miller TL, Mirow A, Mistry S, Mletzko-Crowe T, Modlin LN, Nielsen RE, Nielson EM, Offerhaus SR, O'Keane V, Páleníček T, Printz D, Rademaker MC, van Reemst A, Reinholdt F, Repantis D, Rucker J, Rudow S, Ruffell S, Rush AJ, Schoevers RA, Seynaeve M, Shao S, Soares JC, Somers M, Stansfield SC, Sterling D, Strockis A, Tsai J, Visser L, Wahba M, Williams S, Young AH, Ywema P, Zisook S, Malievskaia E. Goodwin GM, et al. Among authors: feifel d. N Engl J Med. 2022 Nov 3;387(18):1637-1648. doi: 10.1056/NEJMoa2206443. N Engl J Med. 2022. PMID: 36322843 Clinical Trial.
Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial.
Carmi L, Tendler A, Bystritsky A, Hollander E, Blumberger DM, Daskalakis J, Ward H, Lapidus K, Goodman W, Casuto L, Feifel D, Barnea-Ygael N, Roth Y, Zangen A, Zohar J. Carmi L, et al. Among authors: feifel d. Focus (Am Psychiatr Publ). 2022 Jan;20(1):152-159. doi: 10.1176/appi.focus.20103. Epub 2022 Jan 25. Focus (Am Psychiatr Publ). 2022. PMID: 35746941 Free PMC article.
Intranasal oxytocin modulates the salience network in aging.
Liu P, Lin T, Feifel D, Ebner NC. Liu P, et al. Among authors: feifel d. Neuroimage. 2022 Jun;253:119045. doi: 10.1016/j.neuroimage.2022.119045. Epub 2022 Mar 5. Neuroimage. 2022. PMID: 35259525 Free PMC article. Clinical Trial.
106 results